Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

Stomach Neoplasms Clinical Trial

Official title:

A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroesophageal Junction Adenocarcinoma (KEYNOTE-859)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04859582
• Other study ID #: 3475-859 China Extension
• Secondary ID: 2018-001757-27MK
• Status: Withdrawn
• Phase: Phase 3
• Start date: November 8, 2018
• Est. completion date: November 29, 2024

Study information

• Verified date: December 2021
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in combination with chemotherapy (Cisplatin combined with 5-Fluorouracil [FP regimen] or oxaliplatin combined with capecitabine [CAPOX regimen]) versus placebo in combination with chemotherapy (FP or CAPOX regimens) in the treatment of human epidermal growth factor receptor 2 (HER2) negative advanced gastric or GEJ adenocarcinoma in adult Chinese participants.

The primary hypotheses of this study are that pembrolizumab plus chemotherapy is superior to placebo plus chemotherapy in terms of overall survival (OS).

Description:

The China extension study will include participants previously enrolled in China in the global study for MK-3475-859 (NCT03675737) plus those enrolled during the China extension enrollment period. A total of approximately 231 Chinese participants will be enrolled.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: November 29, 2024
• Est. primary completion date: November 29, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• Has histologically or cytologically confirmed diagnosis of locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma with known programmed cell death ligand 1 (PD-L1) expression status

• Has human epidermal growth factor receptor 2 (HER2) negative cancer

• Male participants must agree to use contraception during the intervention period and for at least 95 days after the last dose of chemotherapy, refrain from donating sperm and be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent or must agree to use contraception per study protocol unless confirmed to be azoospermic during this period

• Female participants who are not pregnant, not breastfeeding, and at least one of the following conditions applies: not a woman of childbearing potential (WOCBP) OR is a WOCBP who agrees to use contraception or be abstinent from heterosexual intercourse as their preferred and usual lifestyle during the treatment period and for at least 180 days after the last dose of chemotherapy or for at least 120 days after the last dose of pembrolizumab, whichever is last, and agrees not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period

• Has measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator assessment

• Has provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated

• Has provided tumor tissue sample deemed adequate for PD-L1 biomarker analysis

• Has provided tumor tissue sample for microsatellite instability (MSI) biomarker analysis

• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 3 days prior to the start of study intervention

• Has adequate organ function as demonstrated by laboratory testing within 10 days prior to the start of study treatment

Exclusion Criteria

• Has squamous cell or undifferentiated gastric cancer

• Has had major surgery, open biopsy, or significant traumatic injury within 28 days prior to randomization, anticipation of the need for major surgery during the course of study intervention, or has not recovered adequately from the toxicity and/or complications from previous surgery

• Has preexisting peripheral neuropathy >Grade 1

• Is a WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization or treatment allocation

• Has had previous therapy for locally advanced, unresectable or metastatic gastric/GEJ cancer. Participants may have received prior neoadjuvant and/or adjuvant therapy as long as it was completed =6 months prior to randomization

• Has received prior therapy with an anti-PD-1, anti-PD-L1 or anti- PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX- 40, CD137)

• Has received prior systemic anticancer therapy including investigational agents within 4 weeks prior to randomization or has not recovered from all AEs due to any previous therapies to =Grade 1 or baseline

• Has received prior radiotherapy within 2 weeks prior to study start or has not recovered from all previous radiation-related toxicities, required corticosteroids, and have not had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (=2 weeks of radiotherapy) to noncentral nervous system (CNS) disease

• Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study treatment

• Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment

• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment

• Has a known additional malignancy that is progressing or has required active treatment within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy

• Has known active CNS metastases and/or carcinomatous meningitis

• Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients

• Has an active autoimmune disease that has required systemic treatment in past 2 years

• Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis

• Has an active infection requiring systemic therapy

• Has a known history of human immunodeficiency virus (HIV) infection

• Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as Hepatitis C virus [HCV] ribonucleic acid [RNA] detected qualitatively) infection

• Has a known history of active tuberculosis

• Has hypokalemia (serum potassium less than the lower limit of normal)

• Has hypomagnesemia (serum magnesium less than the lower limit of normal)

• Has hypocalcemia (serum calcium less than the lower limit of normal)

• Has a history or current evidence of any condition (eg, known deficiency of the enzyme dihydropyrimidine dehydrogenase), therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator

• Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study

• Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 180 days after the last dose of chemotherapy or through 120 days after the last dose of pembrolizumab, whichever is last

• Has had an allogenic tissue/solid organ transplant

• Has a known severe hypersensitivity (= Grade 3) to any of the study chemotherapy agents (including, but not limited to, infusional 5-fluorouracil or oral capecitabine) and/or to any of their excipients

• For participants taking cisplatin: has Grade =2 audiometric hearing loss

Related Conditions & MeSH terms

• Adenocarcinoma
• Stomach Neoplasms

Intervention

Biological:
• Pembrolizumab
Administered as an IV infusion on Day 1 Q3W

Drug:
• Cisplatin
Administered as an IV infusion on Day 1 Q3W
• 5-fluorouracil
Administered as a continuous IV infusion on Days 1-5 Q3W
• Oxaliplatin
Administered as an IV infusion on Day 1 Q3W
• Capecitabine
Administered orally BID on Days 1 to 14 Q3W
• Placebo for Pembrolizumab
Administered as an IV infusion on Day 1 Q3W

Locations

Country	Name	City	State
China	Cancer Hospital Chinese Academy of Medical Sciences ( Site 2421)	Beijing	Beijing
China	Peking Union Medical College Hospital ( Site 2425)	Beijing	Beijing
China	The First Hospital of Jilin University ( Site 2416)	Chang chun	Jilin
China	Hunan Cancer Hospital ( Site 2439)	Changsha	Hunan
China	Xiangya Hospital Central-South University ( Site 2419)	Changsha	Hunan
China	Changzhou Cancer Hospital-Changzhou Fourth Peoples Hospital ( Site 2441)	Changzhou	Jiangsu
China	900 Hospital of the Joint ( Site 2418)	Fuzhou	Fujian
China	Fujian Medical University Union Hospital ( Site 2410)	Fuzhou	Fujian
China	Fujian Provincial Cancer Hospital ( Site 2414)	Fuzhou	Fujian
China	Guangdong General Hospital ( Site 2431)	Guangzhou	Guangdong
China	Sir Run Run Show Hospital ( Site 2427)	Hangzhou	Zhejiang
China	Zhejiang Cancer Hospital ( Site 2417)	Hangzhou	Zhejiang
China	Zhejiang Provincial People's Hospital ( Site 2446)	Hangzhou	Zhejiang
China	Harbin Medical University Cancer Hospital ( Site 2401)	Harbin	Heilongjiang
China	The First Affiliated Hospital of Nanchang University ( Site 2440)	Nanchang	Jiangxi
China	Jiangsu Cancer Hospital ( Site 2432)	Nanjing	Jiangsu
China	The 81st Hospital of PLA ( Site 2413)	Nanjing	Jiangsu
China	The Affiliated Hospital of Qingdao University ( Site 2405)	Qingdao	Shandong
China	Shanghai East Hospital ( Site 2403)	Shanghai	Shanghai
China	Zhongshan Hospital affiliated to Fudan University ( Site 2407)	Shanghai	Shanghai
China	Peking University Shenzhen Hospital ( Site 2442)	Shenzhen	Guangdong
China	Cancer Hospital Affiliated to Xinjiang Medical University ( Site 2420)	Urumqi	Xinjiang
China	Hubei Cancer Hospital ( Site 2434)	Wuhan	Hubei
China	The First Affiliated Hospital of Xiamen University ( Site 2430)	Xiamen	Fujian
China	Zhongshan Hospital Xiamen University ( Site 2447)	Xiamen	Fujian
China	1st Affil hosp of Med College of Xi'an Jiaotong University ( Site 2428)	XiAn	Shanxi
China	Yancheng First People s Hospital ( Site 2426)	Yancheng	Jiangsu
China	Henan Cancer Hospital ( Site 2415)	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	OS is the time from randomization to death due to any cause.	Up to approximately 65 months
Secondary	Progression-free Survival (PFS)	PFS is defined as the time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR).	Up to approximately 65 months
Secondary	Objective Response Rate (ORR)	ORR was defined as the percentage of participants who have a confirmed complete response (CR: disappearance of all target lesions) or partial response (PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1 as assessed by BICR.	Up to approximately 65 months
Secondary	Duration of Response (DOR)	DOR is determined by disease assessment and is defined as the time from first response (CR or PR) to disease progression, or death from any cause, whichever occurs first.	Up to approximately 65 months
Secondary	Percentage of Participants Experiencing Adverse Events (AEs)	Percentage of participants experiencing an AE defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study therapy and irrespective of causality to study treatment.	Up to approximately 65 months
Secondary	Percentage of Participants Discontinuing Study Drug Due to AEs	Percentage of participants discontinuing study treatment due to an AE.	Up to approximately 36 months

External Links

•   Merck Oncology Clinical Trials Information